BR0314544A - Compostos para a inibição de rotamases e seu uso - Google Patents

Compostos para a inibição de rotamases e seu uso

Info

Publication number
BR0314544A
BR0314544A BR0314544-1A BR0314544A BR0314544A BR 0314544 A BR0314544 A BR 0314544A BR 0314544 A BR0314544 A BR 0314544A BR 0314544 A BR0314544 A BR 0314544A
Authority
BR
Brazil
Prior art keywords
substituted
heterocyclyl
alkyl
straight
branched
Prior art date
Application number
BR0314544-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Jochen Knolle
Mike Schutkowski
Gerd Hummel
Thomas Tradler
Laurence Jobron
Claudia Christner
Dirk Scharn
Roland Stragies
Christoph Gibson
Frank Osterkamp
Original Assignee
Jerini Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jerini Ag filed Critical Jerini Ag
Publication of BR0314544A publication Critical patent/BR0314544A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
BR0314544-1A 2002-09-18 2003-09-18 Compostos para a inibição de rotamases e seu uso BR0314544A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020020987 EP1402888A1 (en) 2002-09-18 2002-09-18 The use of substituted carbocyclic compounds as rotamases inhibitors
PCT/EP2003/010406 WO2004026815A2 (en) 2002-09-18 2003-09-18 Phenol derivatives and their use as rotamase inhibitors

Publications (1)

Publication Number Publication Date
BR0314544A true BR0314544A (pt) 2005-08-16

Family

ID=31970282

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314544-1A BR0314544A (pt) 2002-09-18 2003-09-18 Compostos para a inibição de rotamases e seu uso

Country Status (14)

Country Link
US (2) US20070054904A1 (https=)
EP (3) EP1402888A1 (https=)
JP (2) JP2005539072A (https=)
KR (1) KR20050053673A (https=)
CN (1) CN100546977C (https=)
AU (1) AU2003271619A1 (https=)
BR (1) BR0314544A (https=)
CA (1) CA2498662A1 (https=)
MX (1) MXPA05003084A (https=)
PL (1) PL374846A1 (https=)
RU (2) RU2005111256A (https=)
SG (1) SG165995A1 (https=)
WO (1) WO2004026815A2 (https=)
ZA (1) ZA200501913B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
PL1701940T3 (pl) * 2003-12-23 2008-11-28 H Lundbeck As Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CN1984899B (zh) * 2004-05-12 2011-07-27 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
JP2008517072A (ja) * 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
WO2006078621A2 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
EP1888052A2 (en) * 2005-05-12 2008-02-20 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
DE602006017694D1 (de) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
TW200726764A (en) 2005-06-27 2007-07-16 Bristol Myers Squibb Co N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
NZ569329A (en) 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
US20080081913A1 (en) * 2006-09-29 2008-04-03 General Electric Company Benzoxazole and benzothiazole compounds and methods therefor
US20080081210A1 (en) 2006-09-29 2008-04-03 General Electric Company Authenticatable articles and methods therefor
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110105602A2 (en) * 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
EP2062578A1 (en) * 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
WO2010057101A2 (en) * 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
SG174214A1 (en) 2009-03-25 2011-10-28 Abbott Lab Antiviral compounds and uses thereof
AU2010235334A1 (en) * 2009-04-06 2011-11-24 Neurotech Pharmaceuticals Co., Ltd. Pharmaceutical composition for treating or preventing burn injuries
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20140296255A1 (en) * 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
US20140329833A1 (en) * 2011-05-19 2014-11-06 Oryzon Genomics, S.A Lysine demethylase inhibitors for inflammatory diseases or conditions
MX2014011615A (es) * 2012-03-28 2015-01-19 Neuropore Therapies Inc Derivados de fenil-urea y fenil-carbamato como inhibidores de agregacion de proteina.
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US20170273922A1 (en) * 2014-10-03 2017-09-28 The Royal Institution For The Advacement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
RU2765181C2 (ru) * 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
CN107417578B (zh) * 2017-08-23 2020-02-07 沈阳海诺威医药科技有限公司 N-(3,5-二甲基金刚烷-1-基)-n’-取代苯基脲类化合物及其制备方法和用途
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN111233692A (zh) * 2020-01-19 2020-06-05 江西农业大学 一种香茅酸酰胺类衍生物及其制备方法与应用
WO2023003468A1 (en) 2021-07-23 2023-01-26 Rijksuniversiteit Groningen Novel inhibitors of histone deacetylase (hdac), and methods, compositions and uses related thereto.
CN117682973B (zh) * 2022-09-26 2026-03-20 中国药科大学 磺酰胺类化合物及其医药用途
CN116942649B (zh) * 2023-08-01 2025-09-16 华中农业大学 一种苯基脲类化合物作为巴贝斯虫生长抑制剂的应用
CN117224515A (zh) * 2023-10-31 2023-12-15 首都医科大学附属北京朝阳医院 Coh-sr4在制备预防和/或治疗缺血性心脏病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5958949A (en) * 1996-12-31 1999-09-28 Gpi Nil Holdings Inc. N-linked ureas and carbamates of piperidyl thioesters
US6242468B1 (en) * 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
ZA98825B (en) * 1997-02-27 1998-10-19 Guilford Pharm Inc Method of using neurotrophic carbamates and ureas
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JP2003508512A (ja) * 1999-09-08 2003-03-04 ギルフォード ファーマシュウティカルズ インコーポレイテッド 非ペプチド性サイクロフィリン結合化合物とその用途
EP1339668A2 (en) * 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6656971B2 (en) * 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
JP2002241273A (ja) * 2001-02-13 2002-08-28 Sumitomo Pharmaceut Co Ltd ベンズアミド誘導体およびその利用
US20040063742A1 (en) * 2001-02-15 2004-04-01 Dan Peters Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
US20040077634A1 (en) * 2001-02-15 2004-04-22 Ulrik Lademann Treatment of diseases characterized by excessive or insufficient cell death

Also Published As

Publication number Publication date
AU2003271619A1 (en) 2004-04-08
EP1539683A2 (en) 2005-06-15
PL374846A1 (en) 2005-11-14
JP2005539072A (ja) 2005-12-22
US20110065760A1 (en) 2011-03-17
US20070054904A1 (en) 2007-03-08
KR20050053673A (ko) 2005-06-08
RU2005111256A (ru) 2006-10-27
RU2010136779A (ru) 2012-03-10
EP2100876A3 (en) 2010-02-24
EP1402888A1 (en) 2004-03-31
CN1701061A (zh) 2005-11-23
SG165995A1 (en) 2010-11-29
CA2498662A1 (en) 2004-04-01
MXPA05003084A (es) 2005-11-17
WO2004026815A2 (en) 2004-04-01
WO2004026815A3 (en) 2004-12-02
ZA200501913B (en) 2005-07-27
JP2011037869A (ja) 2011-02-24
EP2100876A2 (en) 2009-09-16
CN100546977C (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
BR0314544A (pt) Compostos para a inibição de rotamases e seu uso
BR0102607A (pt) Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos
ATE473747T1 (de) NEUE VERWENDUNG DES MIFEPRISTON UND DESSEN DERIVATEN ZUR MODULIERUNG DES ßHEDGEHOGß- PROTEINSIGNALWEGES UND DESSEN ANWENDUNGEN
BR0309534A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0212695A (pt) Composto, composição artropodicida e método para o controle de artrópodes
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
BR0213455A (pt) Composto, seu uso, composição farmacêutica, método para o tratamento ou prevenção de uma doença para a qual um receptor adenosina está relacionado, e método para promover a defecação
BR0214096A (pt) Inibidores da pde9 para o tratamento de distúrbios cardiovasculares
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
BRPI0412488A (pt) derivados de heteroarila e arila trissubstituìdas poro moduladores de metabolismo e a profilaxia e tratamento de distúrbios relacionados a este
BR9908351A (pt) Compostos, processo para a preparação dosmesmos, e, composição farmacêutica
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BR0211477A (pt) Inibidores de polimerase viral
BR122021005860A8 (pt) Derivados de aminoácidos e composição que os compreende
MD3864C2 (ro) Compuşi ai cianoantranilamidei, compoziţii pe baza ei şi procedeu de combatere a dăunătorilor nevertebraţi
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
BRPI0413518A (pt) composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
BRPI0708685B8 (pt) composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
BR0207985A (pt) Inibidores de metaloproteinase
AR046580A1 (es) Derivados de estrona 3,15-sustituidos que representan compuestos inhibidores de deshidrogenasa 17b-hidroxiesteroide de tipo i (17b-hsd1), preparaciones farmaceuticas que los contienen, y procedimientos para su preparacion
BR9809598A (pt) Uso de compostos, e, composto.
BRPI0608819B8 (pt) formas cristalinas de um derivado de imidazol
BR9815920A (pt) Compostos aza-heterocìclicos usados para tratar distúrbios neurológicos e queda de cabelo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/135, A61K 31/17, A61K 31/216, A61K 31/341, A61P 1/04, A61P 1/12, A61P 1/16, A61P 11/00, A61P 15/00, A61P 17/00, A61P 19/02, A61P 21/04, A61P 25/00, A61P 27/02, A61P 29/00, A61P 31/00, A61P 33/00, A61P 35/00, A61P 37/00, A61P 43/00, A61P 9/00, A61P 9/10

Ipc: A61K 31/135 (2011.01), A61K 31/17 (2011.01), A61K

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.